NASDAQ:TARS

Tarsus Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy TARS

*Your capital is at risk

$58.76

+1.35 (+2.35%)

At Close: Jun 03, 2026

Tarsus Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -33.06. In total, the insiders bought 847.4K and sold 221.95K TARS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-33.06
● Buy	847.4K shares
● Sell	221.95K shares
59% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Mar 05, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -33.06. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Neervannan Seshadri Chief Operating Officer	C-Suite Officer	8 020 Value: $471.3K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Neervannan Seshadri Chief Operating Officer	C-Suite Officer	5 097 Value: $299.5K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Mottiwala Aziz Chief Commercial Officer	Officer	5 524 Value: $324.6K
Mar 15, 2026 Buy	Common Stock M-Exempt	Farrow Jeffrey S See Remarks	Officer	13 042 Value: $766.3K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Farrow Jeffrey S See Remarks	Officer	5 022 Value: $295.1K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Azamian Bobak R. President/ceo And Board Chair	CEO / President	16 975 Value: $997.5K
Mar 15, 2026 Buy	Common Stock M-Exempt	Lin Elizabeth Yeu Chief Medical Officer	Officer	2 511 Value: $147.5K
Mar 05, 2026 Buy	Restricted Stock Units A-Award	Azamian Bobak R. President/ceo And Board Chair	CEO / President	60 776 Value: $4.55M
Mar 05, 2026 Buy	Restricted Stock Units A-Award	Lin Elizabeth Yeu Chief Medical Officer	Officer	17 161 Value: $1.29M
Mar 05, 2026 Buy	Restricted Stock Units A-Award	Whitfield Dianne C. Chief Human Resources Officer	Officer	17 161 Value: $1.29M
Mar 05, 2026 Buy	Restricted Stock Units A-Award	Neervannan Seshadri Chief Operating Officer	C-Suite Officer	17 161 Value: $1.29M
Mar 05, 2026 Buy	Stock Option (right to buy) A-Award	Farrow Jeffrey S See Remarks	Officer	30 724 Value: $2.30M
Mar 05, 2026 Buy	Stock Option (right to buy) A-Award	Wahl Bryan General Counsel	Officer	27 310 Value: $2.05M
Mar 05, 2026 Buy	Restricted Stock Units A-Award	Wahl Bryan General Counsel	Officer	17 161 Value: $1.29M
Mar 05, 2026 Buy	Restricted Stock Units A-Award	Farrow Jeffrey S See Remarks	Officer	19 306 Value: $1.45M
Mar 05, 2026 Buy	Stock Option (right to buy) A-Award	Mottiwala Aziz Chief Commercial Officer	Officer	30 724 Value: $2.30M
Mar 05, 2026 Buy	Restricted Stock Units A-Award	Mottiwala Aziz Chief Commercial Officer	Officer	19 306 Value: $1.45M
Mar 05, 2026 Buy	Stock Option (right to buy) A-Award	Neervannan Seshadri Chief Operating Officer	C-Suite Officer	27 310 Value: $2.05M
Mar 05, 2026 Buy	Stock Option (right to buy) A-Award	Whitfield Dianne C. Chief Human Resources Officer	Officer	27 310 Value: $2.05M
Mar 05, 2026 Buy	Stock Option (right to buy) A-Award	Lin Elizabeth Yeu Chief Medical Officer	Officer	27 310 Value: $2.05M
Mar 05, 2026 Buy	Stock Option (right to buy) A-Award	Azamian Bobak R. President/ceo And Board Chair	CEO / President	96 723 Value: $7.24M
Mar 04, 2026 Sell	Common Stock S-Sale	Neervannan Seshadri Chief Operating Officer	C-Suite Officer	8 366 Value: $641.4K
Feb 18, 2026 Buy	Stock Option (right to buy)	Pyott David E I Director	Director	2 500 Value: $81.9K
Feb 18, 2026 Buy	Stock Option (right to buy)	Pyott David E I Director	Director	7 000 Value: $90.8K
Feb 18, 2026 Buy	Restricted Stock Units	Pyott David E I Director	Director	1 383 Value: $87.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT TARSUS PHARMACEUTICALS, INC.

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; a...

Read Full Profile Here